Mohit Trikha, PhD

Dr. Mohit Trikha, a venture partner at ATP (Apple Tree Partners), has more than two decades of drug discovery and development experience. Over his career, he has contributed to the advancement of more than 30 oncology programs and has helped to develop multiple approved cancer medicines. Before joining ATP, Dr. Trikha was Vice President and Head of Oncology Early Development at AbbVie and the site head of AbbVie Bay Area. At AbbVie, he was accountable for leading teams advancing oncology discovery stage programs—including small molecules, bispecifics, ADCs, IO and CAR-T cell therapies—up to clinical proof of concept. He was a core member of oncology business development committees, chaired AbbVie’s Oncology Early Development Review Committee, and led external joint governance collaborations with TeneoBio, Trishula, Calibr, and Jacobio, as well as a multi-therapeutic collaboration with Scripps Research. He also represented AbbVie on the board of California Life Sciences. Prior to AbbVie, Dr. Trikha was President, Chief Scientific Officer, and Head of Triphase Accelerator and served on the Triphase Board of Directors. Prior to this, he worked at Genentech, Ambit, and Centocor/Johnson & Johnson in various research and development roles.

Dr. Trikha received his Ph.D. from the University of Southern California (USC) and was an Assistant Professor of Research at Wayne State University before joining industry.